Yanqin Zhang1, Fang Wang1, Jie Ding2, Hongwen Zhang1, Xiaoyu Liu1, Suxia Wang3, Huijie Xiao1, Yong Yao1, Jingcheng Liu1, Xuhui Zhong1, Na Guan1, Baige Su1, Guohong Wu1, Lixia Yu1. 1. Department of Pediatrics, Peking University First Hospital, No. 1, Xi An Men Da Jie, Beijing, 100034, People's Republic of China. 2. Department of Pediatrics, Peking University First Hospital, No. 1, Xi An Men Da Jie, Beijing, 100034, People's Republic of China. djnc_5855@126.com. 3. Department of Electron Microscopy, Peking University First Hospital, Beijing, China.
Abstract
BACKGROUND: The aim of this study was to analyze the long-term efficacy and safety of angiotensin-converting enzyme inhibitor (ACEi) and ACEi + angiotensin receptor blocker (ARB) treatments in a cohort of children with Alport syndrome (AS). METHODS: This was a respective review of 79 Chinese children with AS who received ACEi alone or combined ACEi + ARB therapy. RESULTS: The mean age of the pediatric patients with AS at onset of treatment was 8.6 ± 4.1 (range 1.5-16.3) years. The mean duration of follow-up was 2.5 ± 1.8 (range 0.5-7.8) years. For analysis, we separated the children into three groups according to proteinuria level before treatment, namely, <25, 25-50, and ≥50 mg/kg/day, respectively; after 1 year of treatment the proteinuria had decreased from 11.0 to 9.7 mg/kg/day, from 34.6 to 15.2 mg/kg/day, and from 73.0 to 50.0 mg/kg/day in each group, respectively. Proteinuria decreased significantly during the first 2 years of treatment and was stable from the third to fifth years of treatment. There was no statistically significant difference in the antiproteinuric effect of the ACEi and ACEi + ARB treatments in patients with severe or less severe mutations after 1 year of therapy. Five children stopped the ACEi + ARB treatment due to a decline in creatinine clearance. CONCLUSION: Our findings demonstrate that early and long-term ACEi and ARB treatments in children with AS is efficient and well tolerated. The antiproteinuric effect of ACEi and ARB is of equal value in children with severe and less severe mutations in the COL4An gene.
BACKGROUND: The aim of this study was to analyze the long-term efficacy and safety of angiotensin-converting enzyme inhibitor (ACEi) and ACEi + angiotensin receptor blocker (ARB) treatments in a cohort of children with Alport syndrome (AS). METHODS: This was a respective review of 79 Chinese children with AS who received ACEi alone or combined ACEi + ARB therapy. RESULTS: The mean age of the pediatric patients with AS at onset of treatment was 8.6 ± 4.1 (range 1.5-16.3) years. The mean duration of follow-up was 2.5 ± 1.8 (range 0.5-7.8) years. For analysis, we separated the children into three groups according to proteinuria level before treatment, namely, <25, 25-50, and ≥50 mg/kg/day, respectively; after 1 year of treatment the proteinuria had decreased from 11.0 to 9.7 mg/kg/day, from 34.6 to 15.2 mg/kg/day, and from 73.0 to 50.0 mg/kg/day in each group, respectively. Proteinuria decreased significantly during the first 2 years of treatment and was stable from the third to fifth years of treatment. There was no statistically significant difference in the antiproteinuric effect of the ACEi and ACEi + ARB treatments in patients with severe or less severe mutations after 1 year of therapy. Five children stopped the ACEi + ARB treatment due to a decline in creatinine clearance. CONCLUSION: Our findings demonstrate that early and long-term ACEi and ARB treatments in children with AS is efficient and well tolerated. The antiproteinuric effect of ACEi and ARB is of equal value in children with severe and less severe mutations in the COL4An gene.
Authors: Oliver Gross; Christoph Licht; Hans J Anders; Bernd Hoppe; Bodo Beck; Burkhard Tönshoff; Britta Höcker; Simone Wygoda; Jochen H H Ehrich; Lars Pape; Martin Konrad; Wolfgang Rascher; Jörg Dötsch; Dirk E Müller-Wiefel; Peter Hoyer; Bertrand Knebelmann; Yves Pirson; Jean-Pierre Grunfeld; Patrick Niaudet; Pierre Cochat; Laurence Heidet; Said Lebbah; Roser Torra; Tim Friede; Katharina Lange; Gerhard A Müller; Manfred Weber Journal: Kidney Int Date: 2011-12-14 Impact factor: 10.612
Authors: Nicholas J A Webb; Chun Lam; Shahnaz Shahinfar; Juergen Strehlau; Thomas G Wells; Gilbert W Gleim; Céline Le Bailly De Tilleghem Journal: Nephrol Dial Transplant Date: 2011-02-01 Impact factor: 5.992
Authors: Nicholas J A Webb; Shahnaz Shahinfar; Thomas G Wells; Rachid Massaad; Gilbert W Gleim; Christine McCrary Sisk; Chun Lam Journal: Pediatr Nephrol Date: 2012-12-04 Impact factor: 3.714